最新消息
News

其他消息

Bened Biomedical signs exclusive agreement with M8 Pharmaceuticals
精神益生菌PS128獲得美國GRAS安全性認證
全球十大精神益生菌關鍵企業名單出爐 台灣益福生醫入列
At Bened Biomedical, our purpose is to help people with brain disorders to have happier lives.
Bened Biomedical signed a deal with a major player in Australian and New Zealand markets
The world’s unique Psychobiotic PS128™ will reach the Balkans.
益福益生菌PS128(TM)榮獲「傑出生技產業獎-潛力標竿獎」
【賀】精神益生菌PS128®榮獲『美國專利認證』
PS128®牽手Nuvanta前進馬來西亞市場!
益福生醫榮獲錦獅獎:亞太精準醫療年度益生菌全球領導品牌獎
PS128® 前進新加坡-與保健品領導品牌Activhealth® 合作推出兩支新品
快樂小星星計畫將於2018/12/31圓滿落幕!
【賀】精神益生菌PS128®榮獲『中國專利認證』
精神益生菌PS128® 進軍南非市場
益福生醫參與SupplySide West 2018 - Las Vegas
NutraIngredients: Use your head, follow your gut: Bened Biomedical's award-winning probiotic product set for market expansion
精神益生菌PS128®進軍法國-益福生醫與Synergia SAS簽訂合作協議
「精神益生菌PS128®」榮獲Nutra Ingredients-Asia Awards「年度最佳益生菌產品」大獎
精神益生菌PS128®榮獲「2018台北生技獎-新創技術獎」肯定
【賀】精神益生菌PS128®再度榮獲『中華民國專利認證』
益福生醫榮獲台灣科技部TIEC前進矽谷補助
PS128® “Smart Kids Probiotics” Product to be Launched in Hong Kong
益福生醫「精神益生菌株PS128®」榮獲第14屆國家新創獎
【賀】精神益生菌PS128®榮獲『韓國專利認證』
【賀】精神益生菌 PS128® 榮獲日本與歐盟十四國專利
益福生醫榮獲新創企業世界大賽(Startup World Cup)台灣區冠軍
益福生醫獲第六屆女性創業菁英賽「新創組」冠軍
新創公司益福生醫與英國OptiBiotix Health簽署策略合作協議
益福生醫榮獲亞洲育成協會2017 AABI火炬國際化獎
調整體質益生菌K56榮獲中華民國專利
陽明大學蔡英傑教授:2017年是自閉症醫學研究突破年
益福生醫參與第一屆國際菌-腸-腦軸線研討會
輕盈益生菌K21獲中華民國與美國專利
亞洲首次精神益生菌改善自閉症孩童行為效的臨床研究啟動
益福生醫與日、韓大廠簽訂精神益生菌國際產業合作協議
精神益生菌 PS128 獲中華民國專利
2015.11.18~2015.11.22 WPAIC 2015世界精神醫學會國際大會

Bened Biomedical signs exclusive agreement with M8 Pharmaceuticals

2020 / 12 / 09

Bened Biomedical has signed an exclusive licensing agreement with Mexico's leading pharmaceutical company M8 Pharmaceuticals (formerly moksha8). The agreement focused on Brazil & Mexico secures M8 exclusive rights to market PS128™, a psychobiotic with several completed as well as ongoing clinical studies, for mental and neurological disorders.

In the last decades, several studies have shown a crosstalk within the brain-gut-microbiome axis and the way gut and brain communicate. This occurs through the dynamic population of microorganisms (the gut microbiome) colonizing the gastrointestinal tract, producing metabolites, and interacting with the enteric nervous system and with the central nervous system. The patented PS128™, a unique Lactobacillus plantarum strain, is the world's only probiotic scientifically proven to increase dopamine and serotonin in the brain, which can help reduce symptoms of stress, depression, autism, and Parkinson's syndrome.

Brazil and Mexico are the two largest economies in Latin America; accounting for 63% of the region's pharmaceutical market and reaching a +10.3% and 7.3% respectively growth rate from 2019 to 2020 Q1. Also, worthy of mention is that CNS therapeutics occupy a considerable portion of the pharmaceutical market in Latin America, accounting for $5.3 billion in 2019. The region is one of the high potential emerging markets identified for Bened Biomedical to expand its global presence with its unique psychobiotics portfolio. This will be M8's first launch of a probiotic product, expanding the company's portfolio of marketed products focused on the central nervous system area.

Joel Barlan, CEO of M8 said: "We are delighted to partner with Bened to bring a novel psychobiotic to market. Our goal is to continue to raise the standards of mental health care, and we continue to be committed to bringing innovative product to Latin American patients. We are well aware of the unmet needs in this area, and our mission is to continue to positively impact the lives and improve the mental health of patients in Brazil & Mexico"

Mr. Frankie Cheng, CEO of Bened Biomedical commented: "We are very honored to partner with a market leader in pharmaceuticals like M8 to bring PS128™ to those who suffer from the psychological and neurological disorders in Latin America. Combining the market power and reputation of M8 with the efficacy of psychobiotic PS128™, which is already proven in more than 30 countries, we trust that the partnership will effectively benefit the people in the regions. The int'l team led by Alain Delpy, Head of Int'l Business Development, will continue to assist M8 to fully develop the CNS market".